TransMedics price target raised to $169 from $117 at Canaccord

Canaccord analyst William Plovanic raised the firm’s price target on TransMedics to $169 from $117 and keeps a Buy rating on the shares. The firm said they posted one of its most impressive quarters to date with a strong beat and raise and increased its target citing a higher revenue outlook, higher comps and a higher premium applied to the comp group.